Q32 Bio Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Q32 BIO INC. | |
| Date: March 11, 2025 | /s/ Jodie Morrison |
|---|---|
| Name: Jodie Morrison | |
| Title: Chief Executive Officer and Director |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jodie Morrison | Chief Executive Officer and Director | March 11, 2025 |
| Jodie Morrison | Principal Executive Officer | |
| /s/ Lee Kalowski | Chief Financial Officer and President | March 11, 2025 |
| Lee Kalowski | Principal Financial Officer and Principal | |
| Accounting Officer | ||
| /s/ David Grayzel | Director | March 11, 2025 |
| David Grayzel | ||
| /s/ Diyong Xu | Director | March 11, 2025 |
| Diyong Xu | ||
| /s/ Isaac Manke | Director | March 11, 2025 |
| Isaac Manke | ||
| /s/ Arthur Tzianabos | Director | March 11, 2025 |
| Arthur Tzianabos | ||
| /s/ Kathleen LaPorte | Director | March 11, 2025 |
| Kathleen LaPorte | ||
| /s/ Mary Thistle | Director | March 11, 2025 |
| Mary Thistle | ||
| /s/ Mark Iwicki | Director | March 11, 2025 |
| Mark Iwicki | ||
| /s/ Bill Lundberg | Director | March 11, 2025 |
| Bill Lundberg | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 0042) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Operations for the Years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Comprehensive Loss for the Years ended December 31, 2024 and 2023 | F-7 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years ended December 31, 2024 and 2023 | F-8 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2024 and 2023 | F-9 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.